Apollo Health Ventures is a transatlantic venture capital firm managing over USD 300 million in assets. We specialize in investing in transformative biotechnology companies at primarely the Seed and Series A stages, with a strong focus on innovations targeting age-related diseases and their underlying biological mechanisms. In addition to direct investments, Apollo is deeply committed to venture creation, collaborating with academic founders to translate groundbreaking research into successful drug development and impactful therapies.

Capital under management
Apollo Health Ventures offers a differentiated financing approach that combines active venture creation with early-stage investing in best-in-class companies. Through its Venture Lab, Apollo partners closely with leading scientific experts to transform untapped technologies into high-impact biotechnology companies. The firm provides deep scientific and operational expertise, builds top-tier management teams and ensures access to capital through strong syndicates. In parallel, Apollo invests in outstanding companies founded on breakthrough science, supporting exceptional founders to accelerate development and value creation.

Industry focus
Apollo invests in innovations across therapeutics, data platforms, and health technology. The firm prioritizes novel therapeutics that address the root causes of chronic diseases, aiming to deliver durable and disease-modifying outcomes.

Portfolio and exits
Apollo Health Ventures has built a transatlantic portfolio that includes company creations such as Booster Therapeutics, as well as early stage investments in companies like Haya Therapeutics and Aeovian Pharmaceuticals each addressing fundamental drivers of disease through cutting-edge science.

contact information

Address: Schlueterstraße 36, 10629 Berlin
E-Mail: info@apollo.vc
Web-Adresse: www.apollo.vc